Barclays PLC Cel Sci Corp Transaction History

Barclays PLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $13,578 - $26,262	-5,263 Reduced 87.19%	773 $3,000
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $147,764 - $289,512	-37,599 Reduced 86.17%	6,036 $24,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $201,313 - $363,498	28,354 Added 185.55%	43,635 $310,000
Q3 2021 Nov 09, 2021	BUY	$7.64 - $12.49 $56,597 - $92,525	7,408 Added 94.09%	15,281 $168,000
Q2 2021 Aug 13, 2021	SELL	$8.68 - $27.49 $195,499 - $619,157	-22,523 Reduced 74.1%	7,873 $69,000
Q1 2021 May 13, 2021	BUY	$12.0 - $27.64 $234,072 - $539,145	19,506 Added 179.12%	30,396 $462,000
Q4 2020 Feb 11, 2021	SELL	$11.05 - $16.62 $50,830 - $76,452	-4,600 Reduced 29.7%	10,890 $127,000
Q3 2020 Nov 12, 2020	SELL	$11.69 - $14.54 $898,107 - $1.12 Million	-76,827 Reduced 83.22%	15,490 $197,000
Q2 2020 Aug 12, 2020	BUY	$9.75 - $17.6 $792,616 - $1.43 Million	81,294 Added 737.49%	92,317 $1.38 Million
Q1 2020 May 13, 2020	SELL	$7.54 - $17.05 $135,818 - $307,121	-18,013 Reduced 62.04%	11,023 $128,000
Q4 2019 Feb 10, 2020	BUY	$6.71 - $9.55 $104,803 - $149,161	15,619 Added 116.41%	29,036 $266,000
Q3 2019 Nov 14, 2019	SELL	$6.0 - $9.6 $21,432 - $34,291	-3,572 Reduced 21.03%	13,417 $120,000
Q2 2019 Aug 14, 2019	BUY	$3.77 - $8.67 $64,048 - $147,294	16,989 New	16,989 $142,000
Q4 2018 Feb 14, 2019	SELL	$2.65 - $4.26 $3,786 - $6,087	-1,429 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$0.83 - $4.16 $1,186 - $5,944	1,429 New	1,429 $6,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.